vimarsana.com

Page 2 - லன்கொனே ஆரோக்கியம் பேர்ல்முத்தேர் புற்றுநோய் மையம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Latest study could help future therapies to sway COVID-19 virus

Latest study could help future therapies to sway COVID-19 virus ANI | Updated: Dec 13, 2020 17:08 IST Washington [US], December 13 (ANI): Study published in the journal cell online revealed that by targeting a single protein cell which appears essential for SARS-CoV-2 to replicate could control the spread of the virus. The latest finding from a pair of studies led by researchers at NYU Grossman School of Medicine and NYU Langone Health s Perlmutter Cancer Center and colleagues at Rockefeller University revealed that a protein named TMEM41B is necessary for the COVID-19virus to reproduce and spread to other cells and hence is a potential weakness that could be targeted by future therapies.

Studies reveal potential weaknesses in SARS-CoV-2 infection — Agenparl

Studies reveal potential weaknesses in SARS-CoV-2 infection — Agenparl
agenparl.eu - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from agenparl.eu Daily Mail and Mail on Sunday newspapers.

Study: TMEM41B transmembrane protein is a critical factor for SARS-CoV-2 replication

Study: TMEM41B transmembrane protein is a critical factor for SARS-CoV-2 replication A single protein that appears necessary for the COVID-19 virus to reproduce and spread to other cells is a potential weakness that could be targeted by future therapies. The molecule, known as transmembrane protein 41 B (TMEM41B), is believed to help shape the fatty outer membrane that protects the virus genetic material while it replicates inside an infected cell and before it infects another. The latest finding comes from a pair of studies led by researchers at NYU Grossman School of Medicine and NYU Langone Health s Perlmutter Cancer Center, and colleagues at Rockefeller University and elsewhere.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.